文献速递脊柱关节炎其他结缔组织病

银屑病关节炎与银屑病的比较遗传学分析:发现遗传风险因素与风险预测建模

Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling.
PubMed 文献 · Arthritis Rheumatol · 2022-08-04

研究对5,065例银屑病关节炎(PsA)患者与21,286名健康对照、以及4,340例PsA与6,431例仅皮肤银屑病(PsC)患者分别进行全基因组荟萃分析,发现22q11新易感位点及NF-κB、Wnt等区分通路,PsA遗传力h2SNP=0.63与PsC的0.61相似;已发表分类模型最大AUC仅0.61,风险预测效用有限。

要点

  • 发现22q11新全基因组显著PsA易感位点rs5754467(P=1.61×10-9)。
  • 区分PsA与PsC的关键通路包括NF-κB信号(校正P=1.4×10-45)和Wnt信号(校正P=9.5×10-58)。
  • PsA遗传力h2SNP=0.63,与PsC的h2SNP=0.61相似。

核心结论

  • 研究识别了与PsA发生相关的关键生物学通路,但现有数据集中的风险分类效用有限,可能因本研究中许多PsC患者正在接受对PsA也有效的治疗。
  • 作者认为未来PsA预测模型应在从初级保健招募的PsC患者中测试。

研究设计与样本

  • 对5,065例PsA患者与21,286名健康对照进行全基因组荟萃分析。
  • 对4,340例PsA患者与6,431例PsC患者进行全基因组荟萃分析。
  • 计算基于单核苷酸多态性(SNP)的遗传力估计值(h2SNP),并使用Priority Index软件识别区分PsA与PsC的生物学通路。
  • 探索已发表PsA风险预测流程的泛化性,并开发风险预测模型进行外部验证。

主要发现

  • 发现22q11上一个新的全基因组显著PsA易感位点rs5754467(P=1.61×10-9)。
  • 区分PsA与PsC的关键通路包括NF-κB信号(校正P=1.4×10-45)和Wnt信号(校正P=9.5×10-58)。
  • 本队列中PsA遗传力为中等(h2SNP=0.63),与PsC遗传力(h2SNP=0.61)相似。
  • 已发表分类流程表现中等(最大曲线下面积0.61),基于当前数据衍生的风险模型表现相似。

关键数值与推荐

  • PsA易感位点rs5754467的P=1.61×10-9。
  • NF-κB信号通路校正P=1.4×10-45;Wnt信号通路校正P=9.5×10-58。
  • PsA的h2SNP=0.63;PsC的h2SNP=0.61。
  • 已发表分类流程最大AUC=0.61。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 风险分类在可用数据集中效用有限,可能因为本研究中许多PsC患者正在接受对PsA也有效的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Psoriatic arthritis (PsA) has a strong genetic component, and the identification of genetic risk factors could help identify the ~30% of psoriasis patients at high risk of developing PsA. Our objectives were to identify genetic risk factors and pathways that differentiate PsA from cutaneous-only psoriasis (PsC) and to evaluate the performance of PsA risk prediction models. METHODS: Genome-wide meta-analyses were conducted separately for 5,065 patients with PsA and 21,286 healthy controls and separately for 4,340 patients with PsA and 6,431 patients with PsC. The heritability of PsA was calculated as a single-nucleotide polymorphism (SNP)-based heritability estimate (h2 SNP ) and biologic pathways that differentiate PsA from PsC were identified using Priority Index software. The generalizability of previously published PsA risk prediction pipelines was explored, and a risk prediction model was developed with external validation. RESULTS: We identified a novel genome-wide significant susceptibility locus for the development of PsA on chromosome 22q11 (rs5754467; P = 1.61 × 10-9 ), and key pathways that differentiate PsA from PsC, including NF-κB signaling (adjusted P = 1.4 × 10-45 ) and Wnt signaling (adjusted P = 9.5 × 10-58 ). The heritability of PsA in this cohort was found to be moderate (h2 SNP = 0.63), which was similar to the heritability of PsC (h2 SNP = 0.61). We observed modest performance of published classification pipelines (maximum area under the curve 0.61), with similar performance of a risk model derived using the current data. CONCLUSION: Key biologic pathways associated with the development of PsA were identified, but the investigation of risk classification revealed modest utility in the available data sets, possibly because many of the PsC patients included in the present study were receiving treatments that are also effective in PsA. Future predictive models of PsA should be tested in PsC patients recruited from primary care.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Soomro M, Stadler M, Dand N, et al. Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. Arthritis Rheumatol. 2022. PMID: 35507331. doi:10.1002/art.42154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。